Skip to content

Study · Animal study (in vivo) · mouse · 2016

5 results

Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice.

Kuroki T, Tanaka R, Shimada Y, Yamashiro K, Ueno Y, Shimura H, Urabe T, Hattori N

Stroke15 Mar 2016Cited by 55 (Europe PMC)

PMID26979865 (opens in a new tab)DOI10.1161/strokeaha.116.012934 (opens in a new tab)PepBankPUB-26979865
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In hyperglycemic mice after focal cerebral ischemia, exendin‑4 attenuated matrix metalloproteinase-9 activation.

    In plain wordsIn mice with hyperglycemic stroke, exendin‑4 reduced matrix metalloproteinase-9 activation compared with untreated hyperglycemia.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMatrix metalloproteinase-9 activation
    Study

    mousen: not reported in source

    Hyperglycemic focal cerebral ischemia
    Comparator
    Induced hyperglycemia without exendin-4
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4, but not insulin, attenuated matrix metalloproteinase-9 activation, proinflammatory cytokine (tumor necrosis factor-α) release, and biomarkers of oxidative stress
    3 context sentences
    Summary · context
    Hyperglycemia was induced by intraperitoneal injection of dextrose 15 minutes before transient middle cerebral artery occlusion was performed for 60 minutes using an intraluminal thread.
    Summary · context
    We assessed 4 groups: (1) normal glucose (vehicle control), (2) induced hyperglycemia, (3) induced hyperglycemia with insulin treatment, and (4) induced hyperglycemia with exendin-4 treatment.
    Summary · context
    Neurovascular injuries in brains from each group were evaluated 24 hours and 7 days post ischemia.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In hyperglycemic mice after focal cerebral ischemia, exendin‑4 attenuated tumor necrosis factor-α release.

    In plain wordsIn mice with hyperglycemic stroke, exendin‑4 reduced TNF-alpha release compared with untreated hyperglycemia.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTNF-alpha release
    Study

    mousen: not reported in source

    Hyperglycemic focal cerebral ischemia
    Comparator
    Induced hyperglycemia without exendin-4
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4, but not insulin, attenuated matrix metalloproteinase-9 activation, proinflammatory cytokine (tumor necrosis factor-α) release, and biomarkers of oxidative stress
    3 context sentences
    Summary · context
    Hyperglycemia was induced by intraperitoneal injection of dextrose 15 minutes before transient middle cerebral artery occlusion was performed for 60 minutes using an intraluminal thread.
    Summary · context
    We assessed 4 groups: (1) normal glucose (vehicle control), (2) induced hyperglycemia, (3) induced hyperglycemia with insulin treatment, and (4) induced hyperglycemia with exendin-4 treatment.
    Summary · context
    Neurovascular injuries in brains from each group were evaluated 24 hours and 7 days post ischemia.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In hyperglycemic mice after focal cerebral ischemia, exendin‑4 attenuated oxidative stress biomarkers.

    In plain wordsIn mice with hyperglycemic stroke, exendin‑4 reduced oxidative stress markers compared with untreated hyperglycemia.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseOxidative stress biomarkers
    Study

    mousen: not reported in source

    Hyperglycemic focal cerebral ischemia
    Comparator
    Induced hyperglycemia without exendin-4
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4, but not insulin, attenuated matrix metalloproteinase-9 activation, proinflammatory cytokine (tumor necrosis factor-α) release, and biomarkers of oxidative stress
    3 context sentences
    Summary · context
    Hyperglycemia was induced by intraperitoneal injection of dextrose 15 minutes before transient middle cerebral artery occlusion was performed for 60 minutes using an intraluminal thread.
    Summary · context
    We assessed 4 groups: (1) normal glucose (vehicle control), (2) induced hyperglycemia, (3) induced hyperglycemia with insulin treatment, and (4) induced hyperglycemia with exendin-4 treatment.
    Summary · context
    Neurovascular injuries in brains from each group were evaluated 24 hours and 7 days post ischemia.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In hyperglycemic mice, exendin‑4 inhibited infarct growth at 24 hours after ischemia compared with untreated hyperglycemia.

    In plain wordsIn hyperglycemic mice, exendin‑4 reduced infarct growth at 24 hours compared with untreated hyperglycemia.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInfarct growth at 24 hours
    Study

    mousen: not reported in source

    Hyperglycemic focal cerebral ischemia
    Comparator
    Induced hyperglycemia without exendin-4
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and showed significant inhibition of infarct growth at 24 hours (23.6±0.97 versus 36.3±1.20; P<0.001) and at 7 days after ischemia
    3 context sentences
    Summary · context
    Hyperglycemia was induced by intraperitoneal injection of dextrose 15 minutes before transient middle cerebral artery occlusion was performed for 60 minutes using an intraluminal thread.
    Summary · context
    We assessed 4 groups: (1) normal glucose (vehicle control), (2) induced hyperglycemia, (3) induced hyperglycemia with insulin treatment, and (4) induced hyperglycemia with exendin-4 treatment.
    Summary · context
    Neurovascular injuries in brains from each group were evaluated 24 hours and 7 days post ischemia.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In hyperglycemic mice, exendin‑4 inhibited infarct growth at 7 days after ischemia compared with untreated hyperglycemia.

    In plain wordsIn hyperglycemic mice, exendin‑4 reduced infarct growth at 7 days compared with untreated hyperglycemia.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInfarct growth at 7 days
    Study

    mousen: not reported in source

    Hyperglycemic focal cerebral ischemia
    Comparator
    Induced hyperglycemia without exendin-4
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and showed significant inhibition of infarct growth at 24 hours (23.6±0.97 versus 36.3±1.20; P<0.001) and at 7 days after ischemia
    3 context sentences
    Summary · context
    Hyperglycemia was induced by intraperitoneal injection of dextrose 15 minutes before transient middle cerebral artery occlusion was performed for 60 minutes using an intraluminal thread.
    Summary · context
    We assessed 4 groups: (1) normal glucose (vehicle control), (2) induced hyperglycemia, (3) induced hyperglycemia with insulin treatment, and (4) induced hyperglycemia with exendin-4 treatment.
    Summary · context
    Neurovascular injuries in brains from each group were evaluated 24 hours and 7 days post ischemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.